We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio
Read MoreHide Full Article
For Immediate Releases
Chicago, IL – May 13, 2026 – Zacks.com announces the list of stocks and featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include NVIDIA Corp. (NVDA - Free Report) , Mastercard Inc. (MA - Free Report) , AbbVie Inc. (ABBV - Free Report) , Waterstone Financial, Inc. (WSBF - Free Report) and Precipio, Inc. (PRPO - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for NVIDIA, Mastercard and AbbVie
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp., Mastercard Inc. and AbbVie Inc., as well as two micro-cap stocks Waterstone Financial, Inc. and Precipio, Inc.The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
Shares of NVIDIA have gained +70.1% over the past year against the Zacks Semiconductor - General industry’s gain of +79.1%. The company is benefiting from the strong growth of artificial intelligence (AI) and high-performance accelerated computing. The growing demand for generative AI and large language models using graphics processing units (GPUs) based on NVIDIA’s Hopper and Blackwell architectures is aiding data center revenues.
The continued ramp-up of Ada RTX GPU workstations in the ProViz end market, following the normalization of channel inventory, is acting as a tailwind. Collaborations with more than 320 automakers and tier-one suppliers are likely to advance its presence in the autonomous vehicle space.
However, a limited supply of Blackwell GPUs may hinder its ability to meet demand. Rising costs associated with the production of more complex AI systems will hurt margins. The U.S.-China tech war and rising competition from AMD remain major concerns.
Mastercard’s shares have declined -12.5% over the past year against the Zacks Financial Transaction Services industry’s decline of -24.2%. The company’s rebates and incentives are rising with new and renewed deals, and management expects operating expenses to keep growing as it funds safety, security, digital and B2B initiatives. Geopolitical disruption is weighing on cross-border travel. Valuation remains elevated, supporting a Neutral view.
Nevertheless, Mastercard’s scale and brand strength continue to support steady payment network growth, helped by stable consumer and business spending and higher transaction activity. Cross-border and contactless adoption remain key long-term drivers, and value-added services keep diversifying revenue through cybersecurity, analytics and digital authentication.
Partnerships and targeted acquisitions also extend reach into new payment flows, including stablecoin infrastructure. Share repurchases and dividends remain supported.
Shares of AbbVie have gained +13.3% over the past year against the Zacks Large Cap Pharmaceuticals industry’s gain of +23.6%. The company beats first-quarter estimates for both earnings and sales. It has successfully navigated Humira's loss of exclusivity (LOE) by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications, and should support top-line growth in the next few years.
AbbVie’s neuroscience portfolio is also rapidly expanding and contributing significantly to top-line growth. AbbVie boasts a robust pipeline and expects important data readouts, regulatory submissions and approvals throughout 2026. It has been on an acquisition spree in the past couple of years to bolster its early-stage pipeline that should drive long-term growth.
However, the company faces several headwinds, such as Humira LOE impact, slowing oncology sales and continued macro headwinds for Aesthetics.
Waterstone Financial’s shares have outperformed the Zacks Financial - Savings and Loan industry over the past year (+50.3% vs. +16.7%). This microcap company with a market capitalization of $331.09 million delivered a strong earnings rebound in Q1 2026 as higher asset yields and easing funding costs expanded net interest margin to 2.97% from 2.47%, driving EPS growth. Mortgage banking returned to profitability, supported by a 31% increase in originations and a sharp refinancing recovery.
The company maintains strong capital and liquidity, with risk-based capital above 20% and substantial unused FHLB borrowing capacity. Management also remains shareholder-friendly through dividends and sizable buybacks, including authorization covering nearly 12% of shares outstanding.
However, risks include weakening credit quality, heavy near-term deposit repricing exposure, reliance on wholesale funding and rising operating expenses that could pressure margins if mortgage activity slows. Shares trade below peer valuation levels at 11.05X earnings and 0.95X book value.
Shares of Precipio have outperformed the Zacks Medical Info Systems industry over the past year (+302.8% vs. -34.2%). This microcap company with a market capitalization of $50.81 million has its investment thesis centered on the scalability of its pathology platform and integrated lab-and-diagnostics model. Its core pathology business continues to demonstrate operating leverage, supporting margin expansion and stronger cash generation as volumes grow.
Management is also positioning the Products division for broader commercialization through expanded sales capabilities and distributor relationships. The hybrid operating structure supports recurring customer engagement and cross-selling opportunities, including the planned AML molecular testing launch.
However, the story remains execution-sensitive due to liquidity constraints and product-margin volatility. Investors must balance scalability potential against financing risks. Valuation levels imply a cautious market despite improving profitability, creating upside if execution improves.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio
For Immediate Releases
Chicago, IL – May 13, 2026 – Zacks.com announces the list of stocks and featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include NVIDIA Corp. (NVDA - Free Report) , Mastercard Inc. (MA - Free Report) , AbbVie Inc. (ABBV - Free Report) , Waterstone Financial, Inc. (WSBF - Free Report) and Precipio, Inc. (PRPO - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for NVIDIA, Mastercard and AbbVie
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp., Mastercard Inc. and AbbVie Inc., as well as two micro-cap stocks Waterstone Financial, Inc. and Precipio, Inc.The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> CPI Inflation Rate Heats Up to +3.8%
Today's Featured Research Reports
Shares of NVIDIA have gained +70.1% over the past year against the Zacks Semiconductor - General industry’s gain of +79.1%. The company is benefiting from the strong growth of artificial intelligence (AI) and high-performance accelerated computing. The growing demand for generative AI and large language models using graphics processing units (GPUs) based on NVIDIA’s Hopper and Blackwell architectures is aiding data center revenues.
The continued ramp-up of Ada RTX GPU workstations in the ProViz end market, following the normalization of channel inventory, is acting as a tailwind. Collaborations with more than 320 automakers and tier-one suppliers are likely to advance its presence in the autonomous vehicle space.
However, a limited supply of Blackwell GPUs may hinder its ability to meet demand. Rising costs associated with the production of more complex AI systems will hurt margins. The U.S.-China tech war and rising competition from AMD remain major concerns.
(You can read the full research report on NVIDIA here >>>)
Mastercard’s shares have declined -12.5% over the past year against the Zacks Financial Transaction Services industry’s decline of -24.2%. The company’s rebates and incentives are rising with new and renewed deals, and management expects operating expenses to keep growing as it funds safety, security, digital and B2B initiatives. Geopolitical disruption is weighing on cross-border travel. Valuation remains elevated, supporting a Neutral view.
Nevertheless, Mastercard’s scale and brand strength continue to support steady payment network growth, helped by stable consumer and business spending and higher transaction activity. Cross-border and contactless adoption remain key long-term drivers, and value-added services keep diversifying revenue through cybersecurity, analytics and digital authentication.
Partnerships and targeted acquisitions also extend reach into new payment flows, including stablecoin infrastructure. Share repurchases and dividends remain supported.
(You can read the full research report on Mastercard here >>>)
Shares of AbbVie have gained +13.3% over the past year against the Zacks Large Cap Pharmaceuticals industry’s gain of +23.6%. The company beats first-quarter estimates for both earnings and sales. It has successfully navigated Humira's loss of exclusivity (LOE) by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications, and should support top-line growth in the next few years.
AbbVie’s neuroscience portfolio is also rapidly expanding and contributing significantly to top-line growth. AbbVie boasts a robust pipeline and expects important data readouts, regulatory submissions and approvals throughout 2026. It has been on an acquisition spree in the past couple of years to bolster its early-stage pipeline that should drive long-term growth.
However, the company faces several headwinds, such as Humira LOE impact, slowing oncology sales and continued macro headwinds for Aesthetics.
(You can read the full research report on AbbVie here >>>)
Waterstone Financial’s shares have outperformed the Zacks Financial - Savings and Loan industry over the past year (+50.3% vs. +16.7%). This microcap company with a market capitalization of $331.09 million delivered a strong earnings rebound in Q1 2026 as higher asset yields and easing funding costs expanded net interest margin to 2.97% from 2.47%, driving EPS growth. Mortgage banking returned to profitability, supported by a 31% increase in originations and a sharp refinancing recovery.
The company maintains strong capital and liquidity, with risk-based capital above 20% and substantial unused FHLB borrowing capacity. Management also remains shareholder-friendly through dividends and sizable buybacks, including authorization covering nearly 12% of shares outstanding.
However, risks include weakening credit quality, heavy near-term deposit repricing exposure, reliance on wholesale funding and rising operating expenses that could pressure margins if mortgage activity slows. Shares trade below peer valuation levels at 11.05X earnings and 0.95X book value.
(You can read the full research report on Waterstone Financial here >>>)
Shares of Precipio have outperformed the Zacks Medical Info Systems industry over the past year (+302.8% vs. -34.2%). This microcap company with a market capitalization of $50.81 million has its investment thesis centered on the scalability of its pathology platform and integrated lab-and-diagnostics model. Its core pathology business continues to demonstrate operating leverage, supporting margin expansion and stronger cash generation as volumes grow.
Management is also positioning the Products division for broader commercialization through expanded sales capabilities and distributor relationships. The hybrid operating structure supports recurring customer engagement and cross-selling opportunities, including the planned AML molecular testing launch.
However, the story remains execution-sensitive due to liquidity constraints and product-margin volatility. Investors must balance scalability potential against financing risks. Valuation levels imply a cautious market despite improving profitability, creating upside if execution improves.
(You can read the full research report on Precipio here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.